Want to see MTVA full AI Analyst Report?
MTVA Stock Chart & Stats
$1.68
-$0.06(-4.05%)
At close: 4:00 PM EDT
$1.68
-$0.06(-4.05%)
Day’s Range― - ―
52-Week Range$0.97 - $14.85
Previous CloseN/A
Volume63.12K
Average Volume (3M)80.30K
Market Cap
$10.34M
Enterprise Value-$3.97
Total Cash (Recent Filing)$12.63M
Total Debt (Recent Filing)$177.00K
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Nov 16, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.07
Shares Outstanding6,588,101
10 Day Avg. Volume56,360
30 Day Avg. Volume80,298
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.95
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$14.00Price Target Upside733.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage gives MetaVia a comparatively clean capital structure and reduces near-term interest and refinancing pressure. Positive equity also provides some financial cushion, allowing management to direct available resources toward clinical development rather than servicing substantial debt.
DA-1726 Clinical ProgressProgression to the highest planned doses and reported weight-loss results strengthen the clinical foundation of DA-1726. If later studies confirm tolerability and efficacy, the program could support a differentiated position in the large obesity-treatment market and improve partnering potential.
Potentially Differentiated PharmacologyThe tissue-distribution findings provide a mechanistic rationale for once-weekly dosing, sustained exposure, and observed waist-circumference benefits. This profile may help distinguish DA-1726 from competing obesity therapies, although continued clinical validation remains important for lasting commercial relevance.
Bears Say
Pre-revenue And UnprofitableMetaVia has no commercial revenue to offset development and corporate costs, while recurring losses indicate that its current model cannot yet fund itself. Continued pre-revenue operations leave financial performance dependent on successful clinical advancement and eventual product commercialization.
Persistent Cash BurnSustained negative operating and free cash flow consumes resources needed to advance the pipeline and maintain operations. Even with some improvement from 2024, ongoing burn increases dependence on capital markets or other financing, which can constrain strategic flexibility if funding conditions become less favorable.
Equity Dilution RiskThe at-the-market facility expands access to equity capital, but future share sales can dilute existing ownership and reduce each share's claim on the company. Because MetaVia remains loss-making and cash-burning, repeated financing may become an important structural consideration for shareholders.
MetaVia News
MTVA FAQ
What was MetaVia’s price range in the past 12 months?
MetaVia lowest stock price was $0.97 and its highest was $14.85 in the past 12 months.
What is MetaVia’s market cap?
MetaVia’s market cap is $10.34M.
When is MetaVia’s upcoming earnings report date?
MetaVia’s upcoming earnings report date is Nov 16, 2026 which is in 45 days.
How were MetaVia’s earnings last quarter?
MetaVia released its earnings results on Aug 06, 2026. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.82 by -$0.08.
Is MetaVia overvalued?
According to Wall Street analysts MetaVia’s price is currently Undervalued.
Does MetaVia pay dividends?
MetaVia does not currently pay dividends.
What is MetaVia’s EPS estimate?
MetaVia’s EPS estimate is -0.73.
How many shares outstanding does MetaVia have?
MetaVia has 6,588,101 shares outstanding.
What happened to MetaVia’s price movement after its last earnings report?
MetaVia reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.82. Following the earnings report the stock price went up 2.759%.
Which hedge fund is a major shareholder of MetaVia?
Currently, no hedge funds are holding shares in MTVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MetaVia
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
MTVA Stock 12 Month Forecast
Average Price Target
$14.00
▲(733.33% Upside)
Technical Analysis
Ownership Overview
2.96% Insiders
0.21% Mutual Funds
0.33% Other Institutional Investors
96.24% Public Companies and
Individual Investors